Patents by Inventor Dirk André Emmy Roymans
Dirk André Emmy Roymans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230310573Abstract: The present invention relates to vaccine composition comprising an immunologically effective amount of a viral fusion protein antigen, such as an RSV pre-fusion F protein, and a stabilizing amount of an antiviral compound, and to methods for preparing such vaccine compositions.Type: ApplicationFiled: April 1, 2021Publication date: October 5, 2023Inventors: Tina RITSCHEL, Richard VOORZAAT, Lucy RUTTEN, Mandy Antonia Catharina JONGENEELEN, Tim Hugo Maria JONCKERS, Dirk André Emmy ROYMANS, Johannes Petrus Maria LANGEDIJK
-
Patent number: 11708369Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.Type: GrantFiled: April 19, 2019Date of Patent: July 25, 2023Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: David Francis Alain Lançois, Jérome Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Peter Rigaux, Antoine Benjamin Michaut, Sabrina Dany France Quatrevaux, Sovy Chao, Dirk André Emmy Roymans
-
Patent number: 11491157Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. (Formula I).Type: GrantFiled: January 30, 2019Date of Patent: November 8, 2022Assignee: Janssen Sciences Ireland Unlimited Company Co Cork, IEInventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut
-
Patent number: 11369612Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]pyrazolo[1,5-a]pyrimidin-2-yl]-3-fluoro-phenyl]cyclopropanecarboxylic acid for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and Compound B, a pharmaceutical product comprising Compound A and Compound B, the use of the combination of Compound A and Compound B—or the pharmaceutical product comprising Compound A and Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and Compound B in an effective amount to said subject.Type: GrantFiled: December 4, 2018Date of Patent: June 28, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Nina Ysebaert, Nele Isa E. Goeyvaerts, Dirk André Emmy Roymans, Anil Koul
-
Patent number: 11339165Abstract: The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).Type: GrantFiled: November 28, 2018Date of Patent: May 24, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut, Guillaume Jean Maurice Mercey
-
Publication number: 20220125912Abstract: Compositions including a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.Type: ApplicationFiled: January 10, 2022Publication date: April 28, 2022Inventors: Johannes Petrus Maria LANGEDIJK, Dirk André Emmy ROYMANS
-
Patent number: 11229694Abstract: Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.Type: GrantFiled: October 1, 2019Date of Patent: January 25, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Johannes Petrus Maria Langedijk, Dirk André Emmy Roymans
-
Patent number: 11084826Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.Type: GrantFiled: March 30, 2020Date of Patent: August 10, 2021Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
-
Publication number: 20210236496Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]pyrazolo[1,5-a]pyrimidin-2-yl]-3-fluoro-phenyl]cyclopropanecarboxylic acid for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and Compound B, a pharmaceutical product comprising Compound A and Compound B, the use of the combination of Compound A and Compound B—or the pharmaceutical product comprising Compound A and Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and Compound B in an effective amount to said subject.Type: ApplicationFiled: December 4, 2018Publication date: August 5, 2021Inventors: Nina YSEBAERT, Nele Isa E. GOEYVAERTS, Dirk André Emmy ROYMANS, Anil KOUL
-
Publication number: 20210094958Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.Type: ApplicationFiled: April 19, 2019Publication date: April 1, 2021Inventors: David Francis Alain LANÇOIS, Jérome Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Peter RIGAUX, Antoine Benjamin MICHAUT, Sabrina Dany France QUATREVAUX, Sovy CHAO, Dirk André Emmy ROYMANS
-
Publication number: 20200361942Abstract: The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).Type: ApplicationFiled: November 28, 2017Publication date: November 19, 2020Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Peter RIGAUX, Antoine Benjamin MICHAUT, Guillaume Jean Maurice MERCEY
-
Publication number: 20200360387Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.Type: ApplicationFiled: January 30, 2019Publication date: November 19, 2020Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Peter RIGAUX, Antoine Benjamin MICHAUT
-
Publication number: 20200223855Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.Type: ApplicationFiled: March 30, 2020Publication date: July 16, 2020Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Boris ROGOVOY, Vadim BICHKO, Delphine Yvonne Raymonde LARDEAU, Antoine Benjamin MICHAUT, Anil KOUL
-
Patent number: 10611769Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.Type: GrantFiled: February 11, 2019Date of Patent: April 7, 2020Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
-
Publication number: 20200061183Abstract: Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.Type: ApplicationFiled: October 1, 2019Publication date: February 27, 2020Inventors: Johannes Petrus Maria LANGEDIJK, Dirk André Emmy ROYMANS
-
Patent number: 10456462Abstract: Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.Type: GrantFiled: July 7, 2016Date of Patent: October 29, 2019Assignee: Janssen Vaccines & Preventions B.V.Inventors: Johannes Langedijk, Dirk André Emmy Roymans
-
Publication number: 20190248793Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.Type: ApplicationFiled: February 11, 2019Publication date: August 15, 2019Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Boris ROGOVOY, Vadim BICHKO, Delphine Yvonne Raymonde LARDEAU, Antoine Benjamin MICHAUT, Anil KOUL
-
Patent number: 10208048Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.Type: GrantFiled: April 27, 2016Date of Patent: February 19, 2019Assignee: Janssen Sciences Ireland UCInventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
-
Patent number: 10150761Abstract: The invention concerns novel substituted pyridine-piperazinyl analogs of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.Type: GrantFiled: June 23, 2017Date of Patent: December 11, 2018Assignee: Janssen Sciences Ireland UCInventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Delphine Yvonne Raymonde Lardeau, Xavier Marc Bourdrez, Wendy Mia Albert Balemans, Dirk André Emmy Roymans
-
Publication number: 20180200360Abstract: Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.Type: ApplicationFiled: July 7, 2016Publication date: July 19, 2018Inventors: Johannes LANGEDIJK, Dirk André Emmy ROYMANS